Skip to main
OPRX
OPRX logo

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp has demonstrated robust financial performance, with contracted revenue increasing by 30% year-over-year and revenue outperformance translating into improved margins and earnings per share (EPS). The company is positioned to benefit from the ongoing shift towards digital communication within the pharmaceutical and healthcare provider sectors, with revenue growth expectations in the high teens to low twenties for the near future. Additionally, management's guidance indicates strong revenue visibility for 2025, suggesting over 85% certainty for total revenue and an EBITDA forecast that exceeds consensus estimates, which supports a positive long-term outlook.

Bears say

OptimizeRx operates within the healthcare digital messaging sector but faces structural challenges that may hinder growth, particularly in an increasingly competitive market. Recent financial reports indicate stagnation in revenue growth alongside rising operational costs, which could exert pressure on profitability margins. Additionally, uncertainty surrounding regulatory changes and shifts in healthcare policies may impact its customer acquisition and retention, leading to a potentially negative outlook for future performance.

OptimizeRx Corp (OPRX) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 8 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.